.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AB17_Brincidofovir.Brincidofovir

Information

Brincidofovir is an oral lipid conjugate prodrug of cidofovir, an antiviral medication. It has activity against double-stranded DNA viruses and has been studied for treatment of serious viral infections such as smallpox and cytomegalovirus (CMV) in immunocompromised patients. The drug was granted emergency approval for smallpox under specific circumstances but is not generally approved for widespread clinical use globally.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration.

References

1. Hutson, CL, et al., & Olson, VA (2021). Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model. mSphere 6(1) –. DOI:10.1128/mSphere.00927-20 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33536322

2. Tippin, T, et al., & Naderer, O (2024). Utility of Cytochrome P450 4F2 Genotyping to Assess Drug Interaction Risk for Brincidovovir, a Cytochrome P450 4F2 Substrate. Clinical pharmacology in drug development 13(3) 288–296. DOI:10.1002/cpdd.1356 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38171911

Revisions

• 06/2025 initial generated model